TEAD1 Antibody

1. YAP1 interacts with TEAD1, exerting their transcriptional control over the functional target, glucose transporter 1 (Glut1). PMID: 28892790
2. Post-translational modifications of Yap1 promoting its ubiquitination and apoptosis are characteristic of hepatocellular carcinoma (HCC) with a better prognosis. Conversely, conditions favoring the formation of YAP1-TEAD complexes are associated with aggressive behavior and the acquisition of stemness features by HCC cells. PMID: 27359056
3. TEAD1 and TEAD4 are oncogenic factors, whose aberrant activation is partly mediated by the silencing of miR-377-3p, miR-1343-3p, and miR-4269. PMID: 28759040
4. Adult human and mouse hearts exhibit higher levels of Taz compared to Yap1 in terms of mRNA and protein expression. Moreover, their increases in diseased hearts are proportional, maintaining a consistent Yap1/Taz ratio. Yap1, Taz, and Tead1 accumulate in the nuclear fraction and cardiomyocyte nuclei of diseased hearts. PMID: 29154888
5. Transgenic mice expressing TEAD1 in their skeletal muscle display a significant hyperplasia of muscle stem cells (i.e., satellite cells, SCs) without affecting muscle tissue size. PMID: 27725085
6. This study identifies the YAP1/TEAD1 complex as the representative dysregulated profile of Hippo signaling in osteosarcoma (OS) and provides evidence that targeting TEAD1 could be a therapeutic strategy for this type of cancer. PMID: 28483529
7. MRTF family proteins bind to YAP through a conserved PPXY motif that interacts with the YAP WW domain. This interaction allows MRTF to recruit NcoA3 to the TEAD-YAP transcriptional complex and enhance its transcriptional activity. PMID: 28028053
8. MYC and TEAD activity can be used to stratify different breast cancer subtypes in large panels of breast cancer patients. PMID: 27433809
9. Human papillomavirus 16 E6 induces upregulation of APOBEC3B through increased levels of TEADs, highlighting the importance of the TEAD-APOBEC3B axis in carcinogenesis. PMID: 28077648
10. Elevated levels of transcriptional enhancer activator domain 1 are observed in hepatocellular carcinoma tissues and inversely correlate with miR-590-3p. These findings suggest a tumor suppressor role for miR-590-3p in hepatocellular carcinoma by targeting transcriptional enhancer activator domain 1, making it a potential diagnostic and prognostic marker for liver cancer. PMID: 28349829
11. TEAD1 mediates YAP1 chromatin-binding genome-wide. PMID: 26295846
12. This research shows that the proangiogenic microfibrillar-associated protein 5 (MFAP5) is a direct transcriptional target of YAP/TEAD in cholangiocarcinoma cells. PMID: 26173433
13. TAZ negatively regulates transcription of DeltaNp63 through TEAD1,2,3, and 4 transcription factors. PMID: 25995450
14. This data suggests that Aicardi-Goutières syndrome (AGS) is a genetically heterogeneous disease not restricted to the X chromosome, and TEAD1 mutations may be present in male patients. PMID: 26091538
15. Genetic variants of Hippo pathway genes, particularly YAP1 rs11225163, TEAD1 rs7944031, and TEAD4 rs1990330, may independently or collectively influence the survival of patients with coronary microvascular disease (CM). PMID: 25628125
16. These findings suggest a central role for TEAD and YAP as signal-responsive regulators of multipotent pancreatic progenitors. PMID: 25915126
17. The YAP-TEAD interaction can be disrupted using cyclic YAP-like peptides, which target the HIPPO pathway. PMID: 25384421
18. This research provides the first evidence demonstrating that TEAD1 is a novel general repressor of smooth muscle-specific gene expression by interfering with myocardin binding to SRF. PMID: 24344135
19. An intronic region of the NAIP gene responsive to TEAD1/YAP activity was identified, suggesting that regulation of NAIP by TEAD1/YAP occurs at the transcriptional level. PMID: 23994529
20. Data indicates that knockdown of TEAD1/3/4 induces an almost identical cellular senescent phenotype as YAP silencing. PMID: 23576552
21. This study reveals a new, Livin-dependent, apoptotic role for TEAD1 in mammals, providing mechanistic insight into the downstream consequences of TEAD1 deregulation in cancers. PMID: 23029054
22. TEAD1 exhibits non-AUG translation initiation. PMID: 1851669
23. These findings support two plausible models of cryptic MCAT enhancer regulation by Pur alpha, Pur beta, and MSY1 involving either competitive single-stranded DNA binding or masking of MCAT-bound transcription enhancer factor-1. PMID: 11751932
24. Transcription enhancer factor 1 binds multiple muscle MEF2 and A/T-rich elements during fast-to-slow skeletal muscle fiber type transitions. PMID: 12861002
25. A mutation in the TEAD1 gene is responsible for Sveinsson's chorioretinal atrophy. PMID: 15016762
26. The regulation of IFITM3 by TEF-1 demonstrates that TEF-1 dependent regulation is more extensive than its previously established role in the expression of muscle-specific genes. PMID: 18177740
27. TEAD1 inhibits prolactin gene expression in cultured human uterine decidual cells. PMID: 18775765
28. TEAD1 and the ubiquitin ligase c-Cbl were identified as novel basal cell markers in prostate cancer. PMID: 19002168
29. This study shows that during vertebrate neural tube development, the TEA domain transcription factor (TEAD) is the cognate DNA-binding partner of YAP. PMID: 19015275
30. The primary cellular origin of circumpapillary dysgenesis of the pigment epithelium is within the choroid rather than the pigment epithelium. PMID: 19410955
31. A missense mutation (Y421H) in TEAD1 is strongly associated with Sveinsson's chorioretinal atrophy (SCRA), an autosomal dominant eye disease characterized by symmetrical lesions radiating from the optic disc, affecting both the retina and the choroid. PMID: 15016762
32. TEAD1 (TEF-1) interacts with a muscle-specific cofactor to promote skeletal muscle gene expression. PMID: 12376544

Show More

Hide All

HGNC: 11714

OMIM: 108985

KEGG: hsa:7003

STRING: 9606.ENSP00000354588

UniGene: Hs.655331